RU2015127077A - Лечение поражений полости рта при помощи внеклеточного матрикса плаценты - Google Patents
Лечение поражений полости рта при помощи внеклеточного матрикса плаценты Download PDFInfo
- Publication number
- RU2015127077A RU2015127077A RU2015127077A RU2015127077A RU2015127077A RU 2015127077 A RU2015127077 A RU 2015127077A RU 2015127077 A RU2015127077 A RU 2015127077A RU 2015127077 A RU2015127077 A RU 2015127077A RU 2015127077 A RU2015127077 A RU 2015127077A
- Authority
- RU
- Russia
- Prior art keywords
- extracellular matrix
- oral
- lesion
- human placenta
- subject
- Prior art date
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims 13
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims 13
- 210000002744 extracellular matrix Anatomy 0.000 title claims 13
- 210000002826 placenta Anatomy 0.000 title claims 11
- 210000000214 mouth Anatomy 0.000 title claims 7
- 230000006378 damage Effects 0.000 title claims 4
- 238000000034 method Methods 0.000 claims 39
- 208000025157 Oral disease Diseases 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102000008186 Collagen Human genes 0.000 claims 4
- 108010035532 Collagen Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 229920001436 collagen Polymers 0.000 claims 4
- 239000003599 detergent Substances 0.000 claims 4
- 210000005059 placental tissue Anatomy 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102000007547 Laminin Human genes 0.000 claims 2
- 108010085895 Laminin Proteins 0.000 claims 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 210000002200 mouth mucosa Anatomy 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 102000001187 Collagen Type III Human genes 0.000 claims 1
- 108010069502 Collagen Type III Proteins 0.000 claims 1
- 102000004266 Collagen Type IV Human genes 0.000 claims 1
- 108010042086 Collagen Type IV Proteins 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 1
- 230000001496 desquamative effect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002803 maceration Methods 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000004991 placental stem cell Anatomy 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- -1 zuiklofosfamid Chemical compound 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734665P | 2012-12-07 | 2012-12-07 | |
| US61/734,665 | 2012-12-07 | ||
| PCT/US2013/073593 WO2014089440A1 (en) | 2012-12-07 | 2013-12-06 | Treating oral lesions using placental extracellular matrix |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019101641A Division RU2019101641A (ru) | 2012-12-07 | 2013-12-06 | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015127077A true RU2015127077A (ru) | 2017-01-12 |
Family
ID=50884026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015127077A RU2015127077A (ru) | 2012-12-07 | 2013-12-06 | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты |
| RU2019101641A RU2019101641A (ru) | 2012-12-07 | 2013-12-06 | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019101641A RU2019101641A (ru) | 2012-12-07 | 2013-12-06 | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150313948A1 (https=) |
| EP (2) | EP3838280A1 (https=) |
| JP (4) | JP2016501245A (https=) |
| CN (2) | CN104955465A (https=) |
| BR (1) | BR112015013125A2 (https=) |
| CA (1) | CA2894160C (https=) |
| HK (1) | HK1215391A1 (https=) |
| RU (2) | RU2015127077A (https=) |
| WO (1) | WO2014089440A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2897625B1 (en) | 2012-09-10 | 2019-10-23 | Wake Forest University Health Sciences | Amniotic membrane and its use in wound healing and tissue engineering constructs |
| BR112017003905A2 (en) * | 2014-08-25 | 2018-03-06 | Hli Cellular Therapeutics, Llc. | extracellular matrix compositions |
| US12083245B2 (en) * | 2014-10-02 | 2024-09-10 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| CN110095421B (zh) * | 2019-05-17 | 2022-02-08 | 淮海工学院 | 一种胶原蛋白变性温度的测定方法 |
| CN110975010B (zh) * | 2019-11-25 | 2022-02-15 | 银丰低温医学科技有限公司 | 一种胎盘组织基质材料及其制备方法 |
| CN111494223A (zh) * | 2020-04-22 | 2020-08-07 | 福建汉氏联合干细胞科技有限公司 | 一种胎盘源干细胞漱口修复液 |
| WO2025147712A1 (en) * | 2024-01-05 | 2025-07-10 | Viscus Biologics, Llc | Xenogeneic oral repair compositions and implants thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4185011A (en) | 1978-10-16 | 1980-01-22 | Firma Carl Freudenberg | Process for the production of collagen fibers |
| DE3042860A1 (de) | 1980-11-13 | 1982-06-09 | Heyl & Co Chemisch-Pharmazeutische Fabrik, 1000 Berlin | Kollagenpraeparate, verfahren zu ihrer herstellung und ihre verwendung in der human- und veterinaermedizin |
| FR2516927B1 (fr) | 1981-11-26 | 1986-05-23 | Merieux Fond | Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux |
| US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US4642117A (en) | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
| US5436135A (en) | 1985-09-02 | 1995-07-25 | Pasteur Merieux Serums Et Vaccins | New preparation of placenta collagen, their extraction method and their applications |
| US4852640A (en) | 1986-03-28 | 1989-08-01 | Exothermics-Eclipse Inc. | Recuperative heat exchanger |
| US5660692A (en) | 1988-02-24 | 1997-08-26 | Cedars-Sinai Medical Center | Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers |
| US5008116A (en) | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
| FR2692582B1 (fr) | 1992-06-18 | 1998-09-18 | Flamel Tech Sa | Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux. |
| US5428022A (en) | 1992-07-29 | 1995-06-27 | Collagen Corporation | Composition of low type III content human placental collagen |
| FR2699184B1 (fr) | 1992-12-16 | 1995-03-10 | Flamel Tech Sa | Nouveaux dérivés de collagène, leur procédé d'obtention et leur application à la préparation de biomatériaux. |
| DE69722388T2 (de) | 1996-03-04 | 2004-04-22 | Edwards Lifesciences Corp., Irvine | Nichtpolymere epoxyverbindungen zur vernetzung von biologischem gewebe und daraus hergestellte bioprothesen |
| US5814328A (en) | 1997-01-13 | 1998-09-29 | Gunasekaran; Subramanian | Preparation of collagen using papain and a reducing agent |
| US6117979A (en) | 1997-08-18 | 2000-09-12 | Medtronic, Inc. | Process for making a bioprosthetic device and implants produced therefrom |
| DK1349918T3 (da) | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
| EP2316919B1 (en) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| JP2003119157A (ja) * | 2001-08-06 | 2003-04-23 | Kikuji Yamashita | コラーゲンを含有する洗口剤 |
| JP2005501874A (ja) | 2001-08-31 | 2005-01-20 | ユニバーシティ・オブ・サザン・カリフォルニア | 椎間板及び他のコラーゲン性組織の耐疲労性を向上させ、且つ機械的劣化を低下させるための無毒性架橋試薬の使用 |
| US20030124178A1 (en) * | 2001-12-28 | 2003-07-03 | Haley Jeffrey T. | Soft, adherent, soluble oral patch |
| US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| US20060134201A1 (en) * | 2004-12-16 | 2006-06-22 | Haley Jeffrey T | Collagen troches for treating mouth lesions |
| US7928280B2 (en) * | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| PT2471904T (pt) | 2005-12-29 | 2019-02-25 | Celularity Inc | População de células estaminais placentárias |
| KR20230146124A (ko) * | 2006-10-06 | 2023-10-18 | 셀룰래리티 인코포레이티드 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
| EP2181721A3 (de) * | 2006-11-06 | 2010-05-19 | Lohmann & Rauscher GmbH & Co. KG | Produkt zur Versorgung von Entzündungen, Druckstellen und/oder Aphten im Oralbereich sowie Verwendung eines solchen Produkts |
| EP4559488A3 (en) * | 2007-09-07 | 2025-08-13 | MiMedx Group, Inc. | Placental tissue grafts and improved methods of preparing and using the same |
| CA2818813C (en) * | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
-
2013
- 2013-12-06 EP EP20204692.6A patent/EP3838280A1/en not_active Withdrawn
- 2013-12-06 RU RU2015127077A patent/RU2015127077A/ru not_active Application Discontinuation
- 2013-12-06 WO PCT/US2013/073593 patent/WO2014089440A1/en not_active Ceased
- 2013-12-06 CN CN201380071838.3A patent/CN104955465A/zh active Pending
- 2013-12-06 CA CA2894160A patent/CA2894160C/en active Active
- 2013-12-06 HK HK16103392.0A patent/HK1215391A1/zh unknown
- 2013-12-06 US US14/649,990 patent/US20150313948A1/en not_active Abandoned
- 2013-12-06 BR BR112015013125A patent/BR112015013125A2/pt not_active Application Discontinuation
- 2013-12-06 JP JP2015545874A patent/JP2016501245A/ja active Pending
- 2013-12-06 EP EP13861269.2A patent/EP2928481A4/en not_active Withdrawn
- 2013-12-06 RU RU2019101641A patent/RU2019101641A/ru unknown
- 2013-12-06 CN CN202410084412.1A patent/CN117899116A/zh active Pending
-
2019
- 2019-02-01 JP JP2019016611A patent/JP2019108329A/ja not_active Withdrawn
-
2021
- 2021-01-14 JP JP2021003902A patent/JP2021073217A/ja not_active Withdrawn
-
2023
- 2023-02-09 JP JP2023018047A patent/JP2023065422A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015013125A2 (pt) | 2017-07-11 |
| HK1215391A1 (zh) | 2016-08-26 |
| CA2894160C (en) | 2024-01-02 |
| JP2023065422A (ja) | 2023-05-12 |
| US20150313948A1 (en) | 2015-11-05 |
| EP3838280A1 (en) | 2021-06-23 |
| EP2928481A1 (en) | 2015-10-14 |
| JP2016501245A (ja) | 2016-01-18 |
| RU2019101641A3 (https=) | 2021-12-28 |
| EP2928481A4 (en) | 2016-09-14 |
| JP2019108329A (ja) | 2019-07-04 |
| WO2014089440A1 (en) | 2014-06-12 |
| CN117899116A (zh) | 2024-04-19 |
| CA2894160A1 (en) | 2014-06-12 |
| JP2021073217A (ja) | 2021-05-13 |
| CN104955465A (zh) | 2015-09-30 |
| RU2019101641A (ru) | 2019-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015127077A (ru) | Лечение поражений полости рта при помощи внеклеточного матрикса плаценты | |
| JP2016501245A5 (https=) | ||
| CN103432627B (zh) | 一种制备动物脱细胞组织基质材料的方法及其制备的组织基质材料 | |
| Piccoli et al. | Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch | |
| PE20110435A1 (es) | Composiciones antagonistas del pd-1 | |
| Veterinarie | Cell therapy for tendon repair in horses: an experimental study | |
| AR084753A1 (es) | Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp) | |
| CN103783031B (zh) | 一种细胞保存液 | |
| ES2625145T3 (es) | Aplicación tópica y formulación de eritropoyetina para cicatrizar heridas cutáneas | |
| MX2010003019A (es) | Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia. | |
| EA201390220A1 (ru) | Высоко биосовместимые композиции хитозана/солей глюкозамина с двусторонним термогелеобразованием | |
| MX385305B (es) | Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel. | |
| EA201890516A1 (ru) | Клинические композиции | |
| WO2009136291A3 (en) | Cellular extracts | |
| WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
| US10765698B2 (en) | Treatment of disease with poly-N-acetylglucosamine nanofibers | |
| TR201911076T4 (tr) | Klorür içeriği azaltılmış fosfolipit içeren veya içermeyen hipotonik sulu bileşim. | |
| NZ608202A (en) | Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof | |
| RU2013109370A (ru) | Композиция для восстановления нормальной ткани из фиброзной ткани | |
| CN101507831B (zh) | 一种促进手术伤口愈合的材料及其制备方法 | |
| RU2007144168A (ru) | Способ омоложения кожи | |
| Zhang et al. | Intramyocardial injection of tannic acid attenuates postinfarction remodeling: a novel approach to stabilize the breaking extracellular matrix | |
| AR133384A1 (es) | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida | |
| WO2009036220A3 (en) | Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes | |
| WO2010103475A3 (en) | Use of serine protease inhibitors in the treatment of neutropenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190214 |